Australia markets closed

Radiopharm Theranostics Limited (RAD.AX)

ASX - ASX Delayed price. Currency in AUD
Add to watchlist
0.03400.0000 (0.00%)
At close: 03:57PM AEST
Full screen
Previous close0.0340
Open0.0300
Bid0.0430 x N/A
Ask0.0430 x N/A
Day's range0.0300 - 0.0380
52-week range0.0270 - 0.1464
Volume3,129,201
Avg. volume659,693
Market cap15.652M
Beta (5Y monthly)0.88
PE ratio (TTM)N/A
EPS (TTM)-0.1400
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est0.62
  • GlobeNewswire

    Radiopharm Receives Strategic Investment for up to A$18 million

    Lantheus has agreed to make an initial strategic equity investment of A$7.5 million in RadiopharmOffer price for the shares of A$0.05 represents a 47% premium to the last closing price of $0.034 on 19 June 2024Option for Lantheus to invest a further A$7.5m within 6 months on the same termsLantheus will also secure rights to two early preclinical assets in exchange for an A$3m upfront payment pursuant to a transfer and development agreement SYDNEY, June 20, 2024 (GLOBE NEWSWIRE) -- Radiopharm The

  • GlobeNewswire

    RAD receives approval for Phase 1 therapeutic study of PDL1-nanobody in Non-Small Cell Lung Cancer

    SYDNEY, Australia, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD), a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, is pleased to announce it has been granted Human Research Ethics Committee (HREC) approval to commence its First-In-Human Phase I study in Australia for the Company’s therapy for patients with PDL1-positive non-small cell lung cancer (NSCLC). The dose escalation trial of RAD204, which targets PDL1-p

  • Simply Wall St.

    Radiopharm Theranostics Full Year 2023 Earnings: AU$0.11 loss per share (vs AU$0.17 loss in FY 2022)

    Radiopharm Theranostics ( ASX:RAD ) Full Year 2023 Results Key Financial Results Net loss: AU$34.6m (loss widened by...